Organovo Holdings, Inc. (0R02.L)
USD 0.26
(2.08%)
USD 0.26
(2.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.34 Million USD | -68.74% |
| 2022 | 20.31 Million USD | -38.99% |
| 2021 | 33.29 Million USD | -16.59% |
| 2020 | 39.91 Million USD | 40.35% |
| 2019 | 28.44 Million USD | -29.99% |
| 2018 | 40.62 Million USD | -18.47% |
| 2017 | 49.82 Million USD | -27.97% |
| 2016 | 69.18 Million USD | 2.37% |
| 2015 | 67.57 Million USD | 26.34% |
| 2014 | 53.48 Million USD | 6.58% |
| 2013 | 50.18 Million USD | 199.64% |
| 2012 | 16.74 Million USD | 0.0% |
| 2010 | 4275.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 9.47 Million USD | 49.16% |
| 2023 FY | 6.34 Million USD | -68.74% |
| 2023 Q2 | 11.16 Million USD | -24.36% |
| 2023 Q1 | 14.75 Million USD | -27.36% |
| 2023 Q4 | 6.34 Million USD | -28.51% |
| 2023 Q3 | 8.88 Million USD | -20.43% |
| 2022 Q1 | 30.54 Million USD | -8.26% |
| 2022 FY | 20.31 Million USD | -38.99% |
| 2022 Q4 | 20.31 Million USD | -19.0% |
| 2022 Q3 | 25.07 Million USD | -10.14% |
| 2022 Q2 | 27.91 Million USD | -8.63% |
| 2021 Q1 | 38.29 Million USD | -4.07% |
| 2021 Q2 | 35.88 Million USD | -6.3% |
| 2021 FY | 33.29 Million USD | -16.59% |
| 2021 Q4 | 33.29 Million USD | -5.13% |
| 2021 Q3 | 35.09 Million USD | -2.19% |
| 2020 Q2 | 20.64 Million USD | -19.43% |
| 2020 FY | 39.91 Million USD | 40.35% |
| 2020 Q1 | 25.62 Million USD | -9.92% |
| 2020 Q3 | 21.58 Million USD | 4.54% |
| 2020 Q4 | 39.91 Million USD | 84.96% |
| 2019 Q4 | 28.44 Million USD | -9.17% |
| 2019 Q1 | 43.45 Million USD | 6.96% |
| 2019 Q2 | 37.77 Million USD | -13.07% |
| 2019 Q3 | 31.31 Million USD | -17.1% |
| 2019 FY | 28.44 Million USD | -29.99% |
| 2018 Q3 | 39.68 Million USD | -6.9% |
| 2018 Q2 | 42.62 Million USD | -5.47% |
| 2018 Q1 | 45.09 Million USD | -9.5% |
| 2018 Q4 | 40.62 Million USD | 2.36% |
| 2018 FY | 40.62 Million USD | -18.47% |
| 2017 FY | 49.82 Million USD | -27.97% |
| 2017 Q4 | 49.82 Million USD | -6.96% |
| 2017 Q3 | 53.55 Million USD | -5.9% |
| 2017 Q2 | 56.91 Million USD | -7.78% |
| 2017 Q1 | 61.71 Million USD | -10.8% |
| 2016 Q1 | 58.84 Million USD | -12.92% |
| 2016 Q4 | 69.18 Million USD | -9.13% |
| 2016 Q3 | 76.13 Million USD | 32.32% |
| 2016 Q2 | 57.53 Million USD | -2.23% |
| 2016 FY | 69.18 Million USD | 2.37% |
| 2015 FY | 67.57 Million USD | 26.34% |
| 2015 Q4 | 67.57 Million USD | -9.34% |
| 2015 Q3 | 74.53 Million USD | -8.74% |
| 2015 Q2 | 81.67 Million USD | -9.81% |
| 2015 Q1 | 90.56 Million USD | 69.31% |
| 2014 Q2 | 56.54 Million USD | 20.54% |
| 2014 FY | 53.48 Million USD | 6.58% |
| 2014 Q4 | 53.48 Million USD | 2.73% |
| 2014 Q1 | 46.9 Million USD | -6.53% |
| 2014 Q3 | 52.07 Million USD | -7.91% |
| 2013 Q2 | 54.89 Million USD | 278.4% |
| 2013 Q3 | 51.61 Million USD | -5.98% |
| 2013 FY | 50.18 Million USD | 199.64% |
| 2013 Q4 | 50.18 Million USD | -2.77% |
| 2013 Q1 | 14.5 Million USD | -16.5% |
| 2012 Q1 | 9.7 Million USD | -13.62% |
| 2012 Q3 | 16.74 Million USD | 85.21% |
| 2012 Q2 | 9.04 Million USD | -6.86% |
| 2012 Q4 | 17.37 Million USD | 3.74% |
| 2012 FY | 16.74 Million USD | 0.0% |
| 2011 Q1 | 4275.00 USD | -93.18% |
| 2011 Q2 | 3628.00 USD | -15.13% |
| 2011 Q3 | 3253.00 USD | -10.34% |
| 2011 Q4 | 11.24 Million USD | 345444.11% |
| 2010 FY | 4275.00 USD | 0.0% |
| 2010 Q4 | 62.66 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 98.137% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.171% |
| Codexis, Inc. | 136.56 Million USD | 95.351% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 98.705% |